Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
ARRY vs AVXL: Weighing Solar Momentum Against Biotech Uncertainty

ARRY vs AVXL: Weighing Solar Momentum Against Biotech Uncertainty

Key Takeaways

  • ARRY is a profitable-momentum industrial story tied to solar energy demand, while AVXL is a pre-revenue biotech whose value hinges on regulatory outcomes.
  • ARRY has expanded margins and built a record orderbook in recent quarters, whereas AVXL has faced regulatory setbacks and governance-related headlines.
  • ARRY offers revenue, adjusted earnings, and a tangible backlog; AVXL offers high-upside, high-risk exposure to an Alzheimer's drug candidate.
  • Relative performance has diverged sharply, with ARRY showing positive momentum in recent market activity and AVXL trading near multi-year lows.
  • The two stocks sit in entirely different sectors, making this a comparison of a cyclical industrial versus a binary-outcome biotech.
  • For more detail on each name, explore ARRY Major News and ARRY Today's Price Move, as well as AVXL Major News and AVXL Today's Price Move.
  • To see how algorithmic strategies are positioning across names like these, explore Trending AI Robots.

Introduction

Placing ARRY (Array Technologies) and AVXL (Anavex Life Sciences) side by side highlights two very different businesses: a solar tracking manufacturer and a clinical-stage central nervous system (CNS) biopharmaceutical company. This stock comparison helps investors evaluate a cyclical industrial turnaround against a binary, catalyst-driven biotech. The names suit different risk profiles, yet both have seen notable sentiment shifts recently. Understanding their relative performance, growth drivers, and risk factors can clarify where either might fit in a diversified portfolio. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their industries.

ARRY Overview and Recent Performance

Array Technologies designs and manufactures ground-mount solar tracking systems used in utility-scale and distributed generation solar projects. The company generates tangible revenue and has focused on improving profitability through a shift toward higher-margin domestic business and new product introductions such as OmniTrack and DuraTrack D2S.

In recent quarters, ARRY delivered revenue that topped analyst estimates while building its orderbook to record levels, surpassing $2.4 billion and then $2.5 billion in successive periods. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) and adjusted gross margin improved sequentially, supported by cost actions, domestic content tax credits, and favorable product mix. Analysts have responded constructively, with at least one major firm raising its price target and maintaining a buy rating.

Even so, year-over-year revenue has declined as the company exits lower-margin international business, and full-year guidance has at times trailed some expectations. Recent weeks have shown improving relative momentum in the shares, though the stock remains below its prior highs. Sentiment has been shaped by orderbook growth, margin expansion, and policy support for renewables, balanced against sensitivity to project timing and utility-scale demand cycles. From what I see, the backlog growth stands out as a key positive signal here.

AVXL Overview and Recent Performance

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for CNS disorders. Its lead candidate, blarcamesine (ANAVEX 2-73), targets the sigma-1 receptor and is being studied in Alzheimer's disease, Rett syndrome, and Fragile X syndrome, among other indications. As a pre-revenue developer, the company's value depends heavily on clinical data and regulatory decisions.

Recent market activity for AVXL has been dominated by setbacks. European regulators issued a negative opinion on blarcamesine for early Alzheimer's disease, and the company subsequently withdrew its marketing authorization application in the European Union. Separately, the company disclosed the termination of its chief executive officer and later reported a material weakness in internal control over financial reporting and ineffective disclosure controls. These developments have coincided with shareholder litigation filings.

The shares have declined sharply over recent weeks and now trade near multi-year lows. While the company maintains a cash balance expected to fund operations for an extended runway and continues advancing its pipeline, sentiment has been pressured by governance concerns and regulatory uncertainty. AVXL remains a high-risk, catalyst-dependent story whose outlook hinges on future FDA interactions and clinical milestones.

Head-to-Head Comparison

The clearest contrast between ARRY and AVXL lies in their business models. ARRY is a revenue-generating industrial with a visible orderbook, while AVXL is a pre-revenue biotech dependent on clinical and regulatory milestones. This shapes every other dimension of the comparison.

On growth drivers, ARRY's momentum comes from utility-scale solar demand, margin improvement, and product innovation. AVXL's growth hinges on regulatory approval of its lead asset, making its outcomes more binary. On momentum, ARRY has demonstrated positive trend consistency in recent market activity, whereas AVXL has trended lower amid setbacks.

Risk factors also diverge. ARRY faces commodity costs, project timing, and policy sensitivity; AVXL faces regulatory rejection, governance scrutiny, and dilution risk. Sector exposure further separates them, with ARRY tied to clean energy infrastructure and AVXL to biotechnology. Investors seeking stability and cash flow may find ARRY more suitable, while those pursuing speculative upside may weigh AVXL's catalyst potential against its elevated uncertainty. One thing that stands out is how these profiles appeal to entirely different investor types.

Tickeron AI Verdict

Based on observable factors such as trend consistency, margin momentum, backlog growth, and relative positioning, Tickeron's AI would currently appear to favor ARRY over AVXL. ARRY exhibits more constructive technical momentum, improving fundamentals, and a tangible orderbook, whereas AVXL carries unresolved regulatory and governance overhangs that have weighed on its price trend. This assessment is probabilistic rather than definitive; conditions can shift quickly, particularly around biotech catalysts. Neither company is without risk, and the outcome should be understood as a relative positioning read rather than a guarantee of future performance.

Exploring AI Tools in My Research

When analyzing names like these, I often turn to Tickeron’s AI Trading Bots to test how different automated strategies might perform across market conditions. The platform hosts hundreds of bots, each with its own style, timeframe, and performance history, allowing users to match approaches to shifting regimes rather than relying on a single method. It provides a useful lens for seeing which strategies are currently standing out. AI Trading Bots

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ARRY, AVXL

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


ARRY's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for ARRY moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In 20 of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARRY as a result. In 78 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.

The Moving Average Convergence Divergence Histogram (MACD) for ARRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 38 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

ARRY moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

ARRY broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ARRY entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for ARRY crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.

Following a +40.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARRY advanced for three days, in 191 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.462) is normal, around the industry mean (2.537). P/E Ratio (-6.099) is within average values for comparable stocks, (6.086). Projected Growth (PEG Ratio) (0.399) is also within normal values, averaging (1.699). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.543) is also within normal values, averaging (5.133).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ARRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.

Notable companies

The most notable companies in this group are First Solar (NASDAQ:FSLR), Enphase Energy (NASDAQ:ENPH), SolarEdge Technologies (NASDAQ:SEDG), Canadian Solar (NASDAQ:CSIQ).

Industry description

The alternative power generation industry consists of companies that operate power facilities converting non-conventional forms of energy into electricity. These energy forms are alternatives to fossil fuels, and many of them are derived from natural resources. Alternative energy forms include solar, wind, hydro, and geothermal steam. A major purpose behind using alternative energy – also called ‘clean’ energy - is to address concerns related to the more conventional fossil fuels, such as the latter’s high carbon dioxide emissions which is often considered a factor in global warming. Alternative power generation has been gaining traction in recent years, and could grow further in the future. Large organizations like Google have invested substantially in wind and solar energy-powered electricity. Some of the prominent U.S. companies operating in the alternative power generation industry includes Ormat Technologies, Inc., TerraForm Power, Inc. and NextEra Energy Partners LP.

Market Cap

The average market capitalization across the Alternative Power Generation Industry is 6.02B. The market cap for tickers in the group ranges from 3.39K to 270.64B. CDVM holds the highest valuation in this group at 270.64B. The lowest valued company is MAXNQ at 3.39K.

High and low price notable news

The average weekly price growth across all stocks in the Alternative Power Generation Industry was -24%. For the same Industry, the average monthly price growth was -28%, and the average quarterly price growth was -58%. ZEO experienced the highest price growth at -1%, while SPWR experienced the biggest fall at -54%.

Volume

The average weekly volume growth across all stocks in the Alternative Power Generation Industry was 97%. For the same stocks of the Industry, the average monthly volume growth was 131% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 41
P/E Growth Rating: 44
Price Growth Rating: 76
SMR Rating: 79
Profit Risk Rating: 99
Seasonality Score: -14 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of biopharmaceutical drugs

Industry AlternativePowerGeneration

Industry
Biotechnology
Address
3901 Midway Place NE
Phone
+1 505 881-7567
Employees
1200
Web
https://www.arraytechinc.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.